In addition to the ability to overcome resistance, inhibition of fatty acid uptake and synthesis enhances the therapeutic effect of the dual BCL-2/BCL-XL inhibitor ABT-737 on AML and sensitizes AML patients to conventional chemotherapy, including cytarabine (57–59). This evidence concerns the gene BCL2L1 and acute myeloid leukemia.